• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    20 Stocks Moving in Monday's Pre-Market Session

    1/10/22 6:45:57 AM ET
    $AACG
    $ABSI
    $ADTX
    $BBLG
    Other Consumer Services
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $AACG alert in real time by email


    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Check out these big penny stock gainers and losers

    Losers

    China HGS Real Estate Inc. (NASDAQ:HGSH) fell 12.6% to $3.04 in pre-market trading after jumping over 57% on Friday.

    Absci Corporation (NASDAQ:ABSI) shares fell 7.5% to $6.65 in pre-market trading. Absci shares gained 17% on Friday after the company announced a research collaboration with Merck.

    ATA Creativity Global (NASDAQ:AACG) fell 7.2% to $2.45 in pre-market trading after jumping more than 33% on Friday.

    Marin Software Incorporated (NASDAQ:MRIN) fell 6.6% to $4.23 in pre-market trading. Marin Software shares jumped 31% on Friday after the company announced an integration with Amazon Ads' demand-side platform.

    Aditxt, Inc. (NASDAQ:ADTX) shares fell 6% to $0.4502 in pre-market trading. Aditxt recently signed amendment to extend worldwide licensing agreement, granting exclusivity in all fields of use.

    Koss Corporation (NASDAQ:KOSS) shares fell 5.7% to $10.01 in pre-market trading.

    Xinyuan Real Estate Co., Ltd. (NYSE:XIN) fell 5.7% to $0.7167 in pre-market trading after gaining over 25% on Friday.

    Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares fell 5.3% to $1.08 in pre-market trading after climbing around 12% on Friday.

    Get the next $AACG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AACG
    $ABSI
    $ADTX
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Absci Corporation
    $ABSI
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    Absci Corporation
    $ABSI
    10/2/2025Overweight
    Analyst
    Absci Corporation
    $ABSI
    7/3/2025$7.00Overweight
    Morgan Stanley
    Absci Corporation
    $ABSI
    1/22/2025$9.00Buy
    Needham
    Absci Corporation
    $ABSI
    10/2/2024$10.00Buy
    Guggenheim
    Absci Corporation
    $ABSI
    7/3/2024$7.00Overweight
    Morgan Stanley
    Absci Corporation
    $ABSI
    3/14/2024$13.00Sector Outperform
    Scotiabank
    Absci Corporation
    $ABSI
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas covered exercise/tax liability with 1,469 shares, decreasing direct ownership by 0.45% to 322,703 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    2/4/26 4:53:14 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Mcclain Sean sold $80,015 worth of shares (26,761 units at $2.99), decreasing direct ownership by 0.32% to 8,334,567 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    2/4/26 4:52:29 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    CFO / CBO Jonasson Zachariah sold $52,313 worth of shares (17,496 units at $2.99), decreasing direct ownership by 4% to 383,538 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    2/4/26 4:51:36 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Koss Corporation Reports Second Quarter Results

    MILWAUKEE, Wis., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Koss Corporation (NASDAQ:KOSS) (the "Company"), the U.S. based high-fidelity headphone company, has reported its results for the second quarter ended December 31, 2025. Net sales for the second quarter ended December 31, 2025 were $2,861,379, down $695,707, or 19.6%, from $3,557,086 for the same quarter in the prior year. The company posted a net loss of $565,407 for the three months ended December 31, 2025 versus net income of $94,142 for the same period of the prior fiscal year. Basic and diluted net loss per common share for the second quarter of fiscal year 2026 was $0.06 compared to basic and diluted net income per common share of $0

    1/29/26 5:15:00 PM ET
    $KOSS
    Consumer Electronics/Appliances
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

    DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, having an exercise price of $9.00 per share, at a reduced exercise price of $2.575 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to effective registration statements on Form S-1 (Registration Nos. 333-262407 and

    1/12/26 8:00:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

    BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. "We executed with discipline throughout 2025 as we focused on strengthening the foundation required to advance our clinical program," stated Bone Biologics CEO Jeff Frelick. "During the year, we made meaningful progress across product readiness, intellectual property, and capital structure, including extending the validated shelf life of our rhNELL-1 prot

    1/8/26 8:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Houten Frans bought $148,800 worth of shares (40,000 units at $3.72), increasing direct ownership by 172% to 63,320 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    12/9/25 4:04:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Lillie Lenore bought $12,400 worth of shares (2,500 units at $4.96) (SEC Form 4)

    4 - KOSS CORP (0000056701) (Issuer)

    12/4/25 4:30:03 PM ET
    $KOSS
    Consumer Electronics/Appliances
    Consumer Staples

    Director Pangalos Menelas N bought $254,788 worth of shares (95,785 units at $2.66), increasing direct ownership by 527% to 113,960 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    9/24/25 4:03:44 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AACG
    $ABSI
    $ADTX
    $BBLG
    SEC Filings

    View All

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

    2/6/26 4:03:58 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form 6-K filed by ATA Creativity Global

    6-K - ATA Creativity Global (0001420529) (Filer)

    2/4/26 6:03:35 AM ET
    $AACG
    Other Consumer Services
    Real Estate

    SEC Form SCHEDULE 13G filed by Aditxt Inc.

    SCHEDULE 13G - Aditxt, Inc. (0001726711) (Subject)

    1/30/26 8:02:33 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Analyst initiated coverage on Absci Corporation

    Analyst initiated coverage of Absci Corporation with a rating of Overweight

    10/2/25 8:38:38 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Morgan Stanley resumed coverage on Absci Corporation with a new price target

    Morgan Stanley resumed coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

    7/3/25 7:48:59 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

    Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201 strategy to pursue endometriosis as additional indication; anticipate initiation of Phase 2 clinical trial in the fourth quarter of 2026 Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operat

    11/12/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

    -- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025. "We are very pleased with our performance for the third quarter of 2025." said T.J. Schaefer, CEO of Arcadia. "Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola's largest customer during the third quarter of 2024

    11/7/25 4:05:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

    VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived

    10/29/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Absci Appoints Biopharma Leader Mary Szela to Board of Directors

    VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. "Mary has been a driving force behind the development of one of the most successful therapies in the industry, bringing a rare and invaluable bread

    7/7/25 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

    6/9/25 8:15:00 AM ET
    $ADTX
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AACG
    $ABSI
    $ADTX
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/13/24 11:14:34 AM ET
    $BBLG
    Industrial Specialties
    Health Care